Sepsis, October 21 edition

The investigators developed glutathione-responsive EONPs carrying 4-octyl itaconate and the dihydroorotate dehydrogenase inhibitor EA6. Across transcriptomic, metabolomic, metagenomic, and pharmacological analyses, EONPs reduced systemic hyperinflammation, promoted anti-inflammatory macrophage reprogramming, restored gut microbial homeostasis, increased the microbiota-derived metabolite 5-hydroxyindoleacetic acid, and protected against multi-organ injury in septic models.

Impact: This study advances beyond single-pathway immunomodulation by linking macrophage immunometabolism, systemic inflammation, and gut microbial metabolites within one therapeutic platform. The integrated mechanistic evidence provides a strong preclinical framework for macrophage-targeted nanotherapy, although clinical translation remains untested.

Clinical Implications: The findings support development of macrophage-targeted, immunometabolic nanotherapies for sepsis and suggest that gut microbial metabolites could serve as mechanistic or pharmacodynamic biomarkers. The platform should not yet be used clinically because efficacy, toxicity, pharmacokinetics, and benefit in human sepsis remain unestablished.

Future Directions: Independent replication in multiple clinically relevant animal models should be followed by pharmacokinetic, toxicology, dose-ranging, and manufacturing studies. Subsequent translational work should determine whether 5-hydroxyindoleacetic acid or other microbiome-derived metabolites can identify responders and whether the platform improves outcomes when combined with antibiotics and source control.

In this post hoc analysis of 173 patients from the double-blind VANISH randomized trial, PENK levels of at least 89 pmol/L were associated with higher 28-day mortality. Among patients reaching the maximum vasopressor threshold, high PENK was associated with fewer kidney failure-free days under hydrocortisone than placebo, whereas this pattern was not observed with low PENK; the mortality interaction was not statistically significant.

Impact: The study addresses a clinically important reason for conflicting corticosteroid trial results by testing treatment-effect heterogeneity with a biologically relevant renal biomarker. Its signal that high-PENK patients may experience less favorable kidney outcomes with hydrocortisone is hypothesis-generating and could inform precision sepsis trials.

Clinical Implications: PENK may eventually help select septic shock patients for corticosteroid therapy, particularly when kidney outcomes are considered. However, clinicians should not withhold hydrocortisone based on PENK alone because the analysis was post hoc, the mortality interaction was nonsignificant, and external prospective validation is required.

Future Directions: Prospective biomarker-stratified randomized trials should test whether PENK modifies the benefit-to-harm balance of hydrocortisone, with prespecified renal and mortality outcomes. Replication in diverse septic shock populations and evaluation of PENK kinetics, assay standardization, and interaction with illness severity are also needed.

In 2,143 sepsis patients from the eICU Collaborative Research Database, hospital mortality increased from 8.13% in the mild malnutrition group to 16.14% and 23.27% in the moderate and severe groups. After adjustment, mortality odds were 1.60-fold higher for moderate and 2.66-fold higher for severe malnutrition compared with mild malnutrition; each one-point CONUT increase was associated with a 15% increase in adjusted mortality odds.

Impact: This large cohort supports a simple, routinely calculable nutritional score as an independent prognostic marker in sepsis. Its main value is practical risk stratification and hypothesis generation for nutrition-focused interventions, rather than immediate proof that modifying nutrition improves survival.

Clinical Implications: CONUT scoring may help clinicians identify septic patients who warrant early nutritional assessment, closer monitoring, and consideration of individualized nutrition support. It should complement, rather than replace, established severity scores and clinical judgment because residual confounding and selection bias remain possible.

Future Directions: Prospective multicenter studies should compare CONUT with established severity and nutrition scores, assess whether serial scoring improves prognostic accuracy, and determine whether CONUT-guided nutrition interventions improve patient-centered outcomes. Calibration across different healthcare systems and sepsis phenotypes is also required.